This information is for healthcare professionals, however not intended for UK or Ireland audience.
Are you a healthcare professional (not UK or Ireland)?
About Tegsedi
About Tegsedi
For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now
For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now
Read more
References
mRNA, messenger ribonucleic acid; TTR, transthyretin.
OLE, open-label extension; TTR, transthyretin
- Tegsedi Summary of Product Characteristics. April 2021.
- Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31.
- Coelho T et al. Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis. OPR15, 7th Congress of the European Academy of Neurology 2021, 19-22 June 20.